|
Daily Medical Update
Rheumatoid arthritis
Friday, September 11, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Frontiers in immunology (2026) - Systematic Review
Key Findings
- Subcutaneous methotrexate increased ACR20 response versus oral methotrexate (RR 1.15; 95% CI 1.05–1.25) and increased ACR50 response in the primary random-effects analysis (RR 1.14; 95% CI 1.01–1.29).
- Gastrointestinal adverse events (RR 0.58; 95% CI 0.40–0.83) and diarrhea (RR 0.42; 95% CI 0.21–0.84) were reduced with subcutaneous treatment, while ACR70 and DAS28-ESR did not differ significantly.
📋 Practice Implication: For patients with inadequate response or gastrointestinal intolerance on oral methotrexate, subcutaneous administration is a reasonable escalation before changing drug class, while expectations for deeper response should remain measured.
|
Seminars in arthritis and rheumatism (2026) - Systematic Review
Key Findings
- Selective JAK1 inhibitors were associated with lower overall drug discontinuation than pan-JAK inhibitors (pooled HR 0.72; 95% CI 0.61–0.85; p<0.001).
- Discontinuation for lack of efficacy was lower with selective JAK1 inhibitors (pooled HR 0.68; 95% CI 0.55–0.84), whereas discontinuation for adverse events and infections was similar between groups.
📋 Practice Implication: When a JAK inhibitor is otherwise appropriate, selective JAK1 therapy may offer greater treatment durability primarily through sustained effectiveness rather than a demonstrably safer adverse-event profile.
|
The Lancet. Rheumatology (2026) - Meta-Analysis
Key Findings
- Relative to healthy-weight patients, adjusted ACR20 response was lower with overweight (RR 0.94), class 1 obesity (0.92), class 2 obesity (0.88), and class 3 obesity (0.78); all estimates had 95% CIs excluding 1.00.
- Higher BMI was also associated with worse DAS28-CRP, with adjusted mean differences of 0.14, 0.21, 0.30, and 0.54 across increasing weight categories; no corresponding BMI gradient was observed with placebo.
📋 Practice Implication: BMI should inform counseling and response monitoring during JAK-inhibitor treatment, with weight-management support and earlier reassessment when high BMI coincides with inadequate disease control.
|
Seminars in arthritis and rheumatism (2026) - Systematic Review
Key Findings
- Complete biologic DMARD discontinuation more than doubled flare risk compared with dose reduction or maintenance (pooled RR 2.13; 95% CI 1.74–2.61; p<0.00001).
- After treatment was restarted, the pooled capture rate was 87.5% (95% CI 82.4–91.6), with clinical recovery reached in a median of 12.4 weeks; radiographic progression was minimal and mainly related to cumulative activity during flares.
📋 Practice Implication: For patients in sustained remission who want de-escalation, gradual dose reduction with close disease-activity surveillance is preferable to abrupt biologic withdrawal and should be paired with a rapid restart plan.
|
Clinical and experimental rheumatology (2026) - Systematic Review
Key Findings
- Long-term exposure to low-dose glucocorticoids was associated with increased cardiovascular events (pooled HR 1.37; 95% CI 1.03–1.81; p=0.01).
- The increased cardiovascular risk varied substantially across studies, while the review characterized short-term low-dose use as relatively safer in selected patients than prolonged exposure or higher cumulative doses.
📋 Practice Implication: Use glucocorticoids as a time-limited bridge whenever possible; patients who require longer exposure warrant explicit cardiovascular risk review, mitigation, and tapering plans.
|
|
💡
Summary
The highest-significance evidence supports subcutaneous methotrexate for improved ACR20 response and fewer gastrointestinal adverse events, while selective JAK1 inhibitors show better real-world retention than pan-JAK inhibitors. Higher BMI was associated with weaker JAK-inhibitor response, and biologic DMARD tapering was safer than discontinuation; long-term low-dose glucocorticoids were associated with increased cardiovascular risk.
|
|